Secondary Hyperparathyroidism – Drugs in Development, 2021

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Secondary Hyperparathyroidism – Drugs in Development, 2021, provides an overview of the Secondary Hyperparathyroidism (Hormonal Disorders) pipeline landscape.

Secondary hyperparathyroidism is occurs when the parathyroid glands in neck produce too much parathyroid hormone (PTH) because calcium levels are too low. Symptoms include bone deformities, broken bones, swollen joints and chronic kidney failure. Treatment includes calcimimetic and hormone replacement therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Secondary Hyperparathyroidism – Drugs in Development, 2021, provides comprehensive information on the therapeutics under development for Secondary Hyperparathyroidism (Hormonal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Secondary Hyperparathyroidism (Hormonal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Secondary Hyperparathyroidism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 2, 2, 1, 3 and 3 respectively.

Secondary Hyperparathyroidism (Hormonal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Secondary Hyperparathyroidism (Hormonal Disorders).

– The pipeline guide reviews pipeline therapeutics for Secondary Hyperparathyroidism (Hormonal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Secondary Hyperparathyroidism (Hormonal Disorders) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Secondary Hyperparathyroidism (Hormonal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Secondary Hyperparathyroidism (Hormonal Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Secondary Hyperparathyroidism (Hormonal Disorders).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Secondary Hyperparathyroidism (Hormonal Disorders) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

Amgen Inc

Cinkate Corp

EA Pharma Co Ltd

Lupin Ltd

Mitsubishi Tanabe Pharma Corp

Novadiol Inc

OPKO Health Inc

Scohia Pharma Inc

TaiRx Inc

Vidasym Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Secondary Hyperparathyroidism - Overview

Secondary Hyperparathyroidism - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Secondary Hyperparathyroidism - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Secondary Hyperparathyroidism - Companies Involved in Therapeutics Development

Amgen Inc

Cinkate Corp

EA Pharma Co Ltd

Lupin Ltd

Mitsubishi Tanabe Pharma Corp

Novadiol Inc

OPKO Health Inc

Scohia Pharma Inc

TaiRx Inc

Vidasym Inc

Secondary Hyperparathyroidism - Drug Profiles

calcifediol ER - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cinacalcet - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CK-15 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CTA-091 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Dendocrin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

etelcalcetide hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

evocalcet - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LNP-1892 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SCO-006 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

upacicalcet - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VS-105 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Secondary Hyperparathyroidism - Dormant Projects

Secondary Hyperparathyroidism - Discontinued Products

Secondary Hyperparathyroidism - Product Development Milestones

Featured News & Press Releases

Dec 21, 2020: Launch of Parsabiv intravenous injection syringe for dialysis, a calcimimetic agent in Japan

Jun 29, 2020: ONO receives manufacturing and marketing approval in Japan for Parsabiv intravenous injection syringe for dialysis, a calcimimetic agent

Mar 25, 2020: OPKO Health reports interim results for two ongoing RAYALDEE studies

Sep 04, 2018: OPKO initiates RAYALDEE phase 2 trial in dialysis patients

Jul 16, 2018: OPKO Partner Vifor Fresenius Receives Marketing Approval for RAYALDEE in Canada

May 22, 2018: Kyowa Hakko Kirin Launches ORKEDIA TABLETS (Evocalcet) for the Treatment of Secondary Hyperparathyroidism in Patients on Maintenance Dialysis in Japan

Mar 23, 2018: Kyowa Hakko Kirin Receives Approval for ORKEDIA Tablets (Evocalcet) for the Treatment of Secondary Hyperparathyroidism in Patients on Maintenance Dialysis in Japan

Nov 06, 2017: Kyowa Hakko Kirin Presented Results of Japan Phase III Clinical Study of Evocalcet at Kidney Week 2017 of the American Society of Nephrology

Jun 22, 2017: OPKO Health Announces KDIGO Clinical Practice Guideline Update on CKD-MBD

Jun 05, 2017: OPKO Health Provides Commercial Update for RAYALDEE

Apr 27, 2017: Kyowa Hakko Kirin Submits Application for Approval of Evocalcet (KHK7580) for Secondary Hyperparathyroidism in Maintenance Dialysis Patients in Japan

Feb 15, 2017: Launch of PARSABIV Intravenous Injection for Dialysis, a Calcimimetic Agent, for Treatment of Secondary Hyperparathyroidism in Patients on Hemodialysis

Feb 07, 2017: OPKO Health Promotes Thomas Nusbickel to Renal Division Chief Commercial Officer

Feb 07, 2017: FDA Approves Amgen's Parsabiv (Etelcalcetide), First New Treatment In More Than A Decade For Secondary Hyperparathyroidism In Adult Patients On Hemodialysis

Jan 31, 2017: Kyowa Hakko Kirin Announces Top-Line Results of Phase 3 Clinical Study of KHK7580 with Secondary Hyperparathyroidism in Japan

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Secondary Hyperparathyroidism, 2021

Number of Products under Development by Companies, 2021

Products under Development by Companies, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Secondary Hyperparathyroidism – Pipeline by Amgen Inc, 2021

Secondary Hyperparathyroidism – Pipeline by Cinkate Corp, 2021

Secondary Hyperparathyroidism – Pipeline by EA Pharma Co Ltd, 2021

Secondary Hyperparathyroidism – Pipeline by Lupin Ltd, 2021

Secondary Hyperparathyroidism – Pipeline by Mitsubishi Tanabe Pharma Corp, 2021

Secondary Hyperparathyroidism – Pipeline by Novadiol Inc, 2021

Secondary Hyperparathyroidism – Pipeline by OPKO Health Inc, 2021

Secondary Hyperparathyroidism – Pipeline by Scohia Pharma Inc, 2021

Secondary Hyperparathyroidism – Pipeline by TaiRx Inc, 2021

Secondary Hyperparathyroidism – Pipeline by Vidasym Inc, 2021

Secondary Hyperparathyroidism – Dormant Projects, 2021

Secondary Hyperparathyroidism – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Secondary Hyperparathyroidism, 2021

Number of Products under Development by Companies, 2021

Number of Products by Targets, 2021

Number of Products by Stage and Targets, 2021

umber of Products by Mechanism of Actions, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports